Company Overview of Dr. Reddy's Laboratories Ltd.
Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordanc...
8-2-337, Road No. 3
Founded in 1984
Key Executives for Dr. Reddy's Laboratories Ltd.
Co-Chairman, Chief Executive Officer, Managing Director, Member of the Management Council, Member of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Total Annual Compensation: $6.3M
Chairman of The Board, Member of The Management Council, Chairman of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Total Annual Compensation: $6.3M
Compensation as of Fiscal Year 2015.
Dr. Reddy's Laboratories Ltd. Key Developments
Dr. Reddy's Laboratories Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg
Sep 28 15
Dr. Reddy's Laboratories announced that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM (esomeprazole magnesium) Delayed-Release Capsules in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA). The NEXIUM (esomeprazole magnesium) Delayed-Release Capsules brand and generic had U.S. sales of approximately $5.2 Billion MAT for the most recent twelve months ending in July 2015 according to IMS Health. Dr. Reddy’s ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg are available in bottle count size of 30.
Dr. Reddy's Laboratories Ltd. Approves Adoption of New Articles of Association
Sep 19 15
Dr. Reddy's Laboratories Ltd. announced that the shareholders of the company approved the adoption of new articles of association of the company through the postal ballot.
BioMarin Pharmaceutical Inc. Enters into a Settlement Agreement with Dr. Reddy's Laboratories, Inc
Sep 18 15
BioMarin Pharmaceutical Inc. announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories Inc. that resolves patent litigation in the United States (U.S.) related to BioMarin's Kuvan (sapropterin dihydrochloride) 100mg oral tablets. Under the terms of the settlement, BioMarin will grant Dr. Reddy's a non-exclusive license to its patents related to Kuvan to allow Dr. Reddy to market a generic version of sapropterin dihydrochloride 100mg tablets in the U.S. for the indications approved for Kuvan beginning at a confidential date in the future, but which is more than five years from September 18, 2015, or earlier under certain circumstances. Additional details of the agreement remain confidential. BioMarin continues to vigorously enforce its intellectual property related to Kuvan. This includes continuing its suit against Par Pharmaceutical Inc., which is not affected by this settlement. As required by law, BioMarin and Dr. Reddy will submit the Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries